Multiply Labs Raises $75 Million Series B for Robotic Biomanufacturing

Multiply Labs has raised $75 million in a Series B round to scale its robotic biomanufacturing platform, according to a report by Pulse 2.0.

The round marks the company's largest financing to date and positions Multiply Labs to expand a business built on a specific thesis: pharmaceutical manufacturing should be run by robots, not manual laboratory workflows.

What does Multiply Labs actually build?

Multiply Labs develops robotic systems that automate the production of pharmaceuticals. Its platform applies industrial robotics to biomanufacturing — the process of making medicines and biological products that traditionally depends heavily on manual, hands-on laboratory work.

The core pitch is consistency and speed. Automated, robotic production lines can run around the clock and reduce the variability that comes with human handling. For an industry where manufacturing bottlenecks often slow the path from development to delivered medicine, that automation layer is the product.

The new $75 million will fund the scaling of that platform, Pulse 2.0 reports. Scale, in this context, means extending robotic manufacturing capacity to serve more production demands across the life-sciences sector.

Why is automated biomanufacturing attracting capital?

Pharmaceutical manufacturing has long been one of the least automated corners of advanced industry. Biological production processes — cell handling, formulation, quality-sensitive steps — have resisted the kind of robotic transformation that reshaped automotive and electronics plants.

Multiply Labs sits among the companies working to change that. Its robotic platform targets the manual steps in drug production and replaces them with programmable, repeatable machine operations.

The $75 million Series B signals that investors see commercial demand for that approach, not just technical promise. Capital of this size, directed specifically at scaling a manufacturing platform rather than early research, typically reflects customers already using or contracting for the technology.

What happens next?

The immediate use of proceeds is scaling: multiplying the deployment of robotic biomanufacturing systems beyond their current footprint. Pulse 2.0's report frames the round squarely around that expansion goal.

For the broader sector, the deal is another data point in a widening trend: robotics and automation companies targeting regulated, high-value manufacturing markets where labor intensity and error costs are both high. Multiply Labs now has the balance sheet to test how far robotic biomanufacturing can be pushed — and how quickly the pharmaceutical industry is willing to hand its production lines to machines.